Inhibitors of angiogenesis currently used in clinical practice [11].
Angiogenic inhibitor
Target
Current clinical use
Bevacizumab
VEGF
First approved by the United States Food and Drug Administration (FDA) in February 2004 for patients with metastatic colorectal cancer. Nowadays it is used for other malignancies, including breast cancer.
Sorafenib
VEGFR2 and 3, PDGFR-, FLT3 and KIT
Renal cell carcinoma, Hepatocellular carcinoma,
Sunitinib
PDGFR, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET